In-Hospital Outcomes of Ventricular Tachycardia Catheter Ablation in the Presence of Intra-Cardiac Thrombus.
catheter ablation outcomes
intracardiac thrombus
ventricular tachycardia
Journal
Pacing and clinical electrophysiology : PACE
ISSN: 1540-8159
Titre abrégé: Pacing Clin Electrophysiol
Pays: United States
ID NLM: 7803944
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
revised:
26
07
2024
received:
07
05
2024
accepted:
11
09
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
27
9
2024
Statut:
aheadofprint
Résumé
Ventricular tachycardia (VT) catheter ablation in the presence of intracardiac thrombi was evaluated in very few studies. To investigate in-hospital outcomes of VT ablation in the presence of an intracardiac thrombus, in a large inpatient US registry. Using the National Inpatient Sample (NIS) database, patients who underwent non-elective VT catheter ablations in the United States between 2016 and 2019 were identified using ICD-10 codes. Sociodemographic, clinical data, in-hospital procedures, and outcomes as well as in-hospital mortality were collected. In-hospital outcomes were compared using propensity score (PS) matching analysis with a 1:3 ratio between patients with and without intracardiac thrombus. A weighted total of 15,725 admissions for non-elective VT ablation were included in the study, of which 190 (1.2%) had a discharge diagnosis of intracardiac thrombus. Patients with intracardiac thrombus had a higher comorbidity burden and were more likely to have ischemic cardiomyopathy and a diagnosis of cardiac aneurysm. In PS analysis, the presence of intracardiac thrombus was significantly associated with higher rates of any in-hospital complications (42.1% vs. 19.3%, p < 0.009), driven by higher periprocedural cerebrovascular accident and vascular injury events. In-hospital mortality rates were not significantly different between the groups. In patients undergoing non-elective VT ablation, intracardiac thrombus was associated with higher rates of in-hospital complications, but not higher in-hospital mortality. These findings suggest that intracardiac thrombus should not contraindicate VT ablation when deemed necessary, while efforts should be made to decrease potential complications.
Sections du résumé
BACKGROUND
BACKGROUND
Ventricular tachycardia (VT) catheter ablation in the presence of intracardiac thrombi was evaluated in very few studies.
OBJECTIVES
OBJECTIVE
To investigate in-hospital outcomes of VT ablation in the presence of an intracardiac thrombus, in a large inpatient US registry.
METHODS
METHODS
Using the National Inpatient Sample (NIS) database, patients who underwent non-elective VT catheter ablations in the United States between 2016 and 2019 were identified using ICD-10 codes. Sociodemographic, clinical data, in-hospital procedures, and outcomes as well as in-hospital mortality were collected. In-hospital outcomes were compared using propensity score (PS) matching analysis with a 1:3 ratio between patients with and without intracardiac thrombus.
RESULTS
RESULTS
A weighted total of 15,725 admissions for non-elective VT ablation were included in the study, of which 190 (1.2%) had a discharge diagnosis of intracardiac thrombus. Patients with intracardiac thrombus had a higher comorbidity burden and were more likely to have ischemic cardiomyopathy and a diagnosis of cardiac aneurysm. In PS analysis, the presence of intracardiac thrombus was significantly associated with higher rates of any in-hospital complications (42.1% vs. 19.3%, p < 0.009), driven by higher periprocedural cerebrovascular accident and vascular injury events. In-hospital mortality rates were not significantly different between the groups.
CONCLUSIONS
CONCLUSIONS
In patients undergoing non-elective VT ablation, intracardiac thrombus was associated with higher rates of in-hospital complications, but not higher in-hospital mortality. These findings suggest that intracardiac thrombus should not contraindicate VT ablation when deemed necessary, while efforts should be made to decrease potential complications.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
K.‐H. Kuck, A. Schaumann, L. Eckardt, et al., “Catheter Ablation of Stable Ventricular Tachycardia Before Defibrillator Implantation in Patients With Coronary Heart Disease (VTACH): A Multicentre Randomised Controlled Trial,” Lancet 375, no. 9708 (2010): 31–40, https://doi.org/10.1016/S0140‐6736(09)61755‐4.
V. Y. Reddy, M. R. Reynolds, P. Neuzil, et al., “Prophylactic Catheter Ablation for the Prevention of Defibrillator Therapy,” New England Journal of Medicine 357, no. 26 (2007): 2657–2665, https://doi.org/10.1056/NEJMoa065457.
J. L. Sapp, G. A. Wells, R. Parkash, et al., “Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs,” New England Journal of Medicine 375, no. 2 (2016): 111–121, https://doi.org/10.1056/NEJMoa1513614.
C. Carbucicchio, M. Santamaria, N. Trevisi, et al., “Catheter Ablation for the Treatment of Electrical Storm in Patients With Implantable Cardioverter‐Defibrillators: Short‐ and Long‐Term Outcomes in a Prospective Single‐Center Study,” Circulation 117, no. 4 (2008): 462–469, https://doi.org/10.1161/CIRCULATIONAHA.106.686534.
S. Nayyar, A. N. Ganesan, A. G. Brooks, T. Sullivan, K. C. Roberts‐Thomson, and P. Sanders, “Venturing Into Ventricular Arrhythmia Storm: A Systematic Review and Meta‐Analysis,” European Heart Journal 34, no. 8 (2013): 560–571, https://doi.org/10.1093/eurheartj/ehs453.
K. Zeppenfeld, J. Tfelt‐Hansen, M. de Riva, et al., “2022 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death,” European Heart Journal 43, no. 40 (2022): 3997–4126, https://doi.org/10.1093/eurheartj/ehac262.
H. Calkins, A. Epstein, D. Packer, et al., “Catheter Ablation of Ventricular Tachycardia in Patients With Structural Heart Disease Using Cooled Radiofrequency Energy: Results of a Prospective Multicenter Study. Cooled RF Multi Center Investigators Group,” Journal of the American College of Cardiology 35, no. 7 (2000): 1905–1914.
S. Gunda, S. K. Padala, A. Saini, L. Kang, K. A. Ellenbogen, and J. N. Koneru, “Risk Score Model for Predicting Complications in Patients Undergoing Ventricular Tachycardia Ablation: Insights From the National Inpatient Sample Database,” Europace 21, no. 3 (2019): 475–483, https://doi.org/10.1093/europace/euy213.
I. R. Whitman, R. A. Gladstone, N. Badhwar, et al., “Brain Emboli After Left Ventricular Endocardial Ablation,” Circulation 135, no. 9 (2017): 867–877, https://doi.org/10.1161/CIRCULATIONAHA.116.025546.
E. M. Cronin, F. M. Bogun, P. Maury, et al., “2019 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Catheter Ablation of Ventricular Arrhythmias: Executive Summary,” Journal of Arrhythmia 36, no. 1 (2020): 1–58, https://doi.org/10.1002/joa3.12264.
D. L. Beavers, M. Ghannam, J. Liang, et al., “Diagnosis, Significance, and Management of Ventricular Thrombi in Patients Referred for VT Ablation,” Journal of Cardiovascular Electrophysiology 32, no. 9 (2021): 2473–2483, https://doi.org/10.1111/jce.15177.
T. Bonnin, P. Roumegou, S. Sridi, et al., “Prevalence and Risk Factors of Cardiac Thrombus Prior to Ventricular Tachycardia Catheter Ablation in Structural Heart Disease,” Europace 25, no. 2 (2023): 487–495, https://doi.org/10.1093/europace/euac156.
P. Peichl, D. Wichterle, R. Čihák, B. Aldhoon, and J. Kautzner, “Catheter Ablation of Ventricular Tachycardia in the Presence of an Old Endocavitary Thrombus Guided by Intracardiac Echocardiography,” Pacing and Clinical Electrophysiology 39, no. 6 (2016): 581–587, https://doi.org/10.1111/pace.12844.
V. Zacà, C. Baiocchi, and R. Favilli, “Incessant Ventricular Tachycardia and Concomitant Recurrent Left Ventricular Thrombus: To Ablate or Not to Ablate?,” Europace 17, no. 5 (2015): 833, https://doi.org/10.1093/europace/euv080.
C. Steiner, A. Elixhauser, and J. Schnaier, “The Healthcare Cost and Utilization Project: An Overview,” Effective Clinical Practice 5, no. 3 (2002): 143–151.
C. T. Sciria, E. V. Kogan, J. E. Ip, et al., “Trends and Outcomes of Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic and Nonischemic Cardiomyopathy,” Circulation: Arrhythmia and Electrophysiology 15, no. 4 (2022): e010742, https://doi.org/10.1161/CIRCEP.121.010742.
R. A. Deyo, D. C. Cherkin, and M. A. Ciol, “Adapting a Clinical Comorbidity Index for Use With ICD‐9‐CM Administrative Databases,” Journal of Clinical Epidemiology 45, no. 6 (1992): 613–619, https://doi.org/10.1016/0895‐4356(92)90133‐8.
W. P. Glasheen, T. Cordier, R. Gumpina, G. Haugh, J. Davis, and A. Renda, “Charlson Comorbidity Index: ICD‐9 Update and ICD‐10 Translation,” Am Health Drug Benefits 12, no. 4 (2019): 188–197.
Y.‐T. Chu, Y.‐Y. Ng, and S.‐C. Wu, “Comparison of Different Comorbidity Measures for Use With Administrative Data in Predicting Short‐ and Long‐Term Mortality,” BMC Health Services Research [Electronic Resource] 10 (2010): 140, https://doi.org/10.1186/1472‐6963‐10‐140.
D. Radovanovic, B. Seifert, P. Urban, et al., “Validity of Charlson Comorbidity Index in Patients Hospitalised With Acute Coronary Syndrome. Insights From the Nationwide AMIS Plus Registry 2002–2012,” Heart 100, no. 4 (2014): 288–294, https://doi.org/10.1136/heartjnl‐2013‐304588.
C. Palaniswamy, D. Kolte, P. Harikrishnan, et al., “Catheter Ablation of Postinfarction Ventricular Tachycardia: Ten‐Year Trends in Utilization, In‐Hospital Complications, and In‐Hospital Mortality in the United States,” Heart Rhythm 11, no. 11 (2014): 2056–2063, https://doi.org/10.1016/j.hrthm.2014.07.012.
D. F. Katz, M. P. Turakhia, W. H. Sauer, et al., “Safety of Ventricular Tachycardia Ablation in Clinical Practice: Findings From 9699 Hospital Discharge Records,” Circulation: Arrhythmia and Electrophysiology 8, no. 2 (2015): 362–370, https://doi.org/10.1161/CIRCEP.114.002336.
J. W. Cheung, I. Yeo, J. E. Ip, et al., “Outcomes, Costs, and 30‐Day Readmissions After Catheter Ablation of Myocardial Infarct‐Associated Ventricular Tachycardia in the Real World: Nationwide Readmissions Database 2010 to 2015,” Circulation: Arrhythmia and Electrophysiology 11, no. 11 (2018): e006754, https://doi.org/10.1161/CIRCEP.118.006754.
A. Preda, C. Montalto, M. Galasso, et al., “Fighting Cardiac Thromboembolism During Transcatheter Procedures: An Update on the Use of Cerebral Protection Devices in Cath Labs and EP Labs,” Life (Basel) 13, no. 9 (2023): 1819, https://doi.org/10.3390/life13091819.
P. Peichl, D. Wichterle, L. Pavlu, R. Cihak, B. Aldhoon, and J. Kautzner, “Complications of Catheter Ablation of Ventricular Tachycardia: A Single‐Center Experience,” Circulation: Arrhythmia and Electrophysiology 7, no. 4 (2014): 684–690, https://doi.org/10.1161/CIRCEP.114.001530.
A. A. Hendriks, F. Akca, L. Dabiri Abkenari, et al., “Safety and Clinical Outcome of Catheter Ablation of Ventricular Arrhythmias Using Contact Force Sensing: Consecutive Case Series,” Journal of Cardiovascular Electrophysiology 26, no. 11 (2015): 1224–1229, https://doi.org/10.1111/jce.12762.
W. G. Stevenson, D. J. Wilber, A. Natale, et al., “Irrigated Radiofrequency Catheter Ablation Guided by Electroanatomic Mapping for Recurrent Ventricular Tachycardia After Myocardial Infarction: The Multicenter Thermocool Ventricular Tachycardia Ablation Trial,” Circulation 118, no. 25 (2008): 2773–2782, https://doi.org/10.1161/CIRCULATIONAHA.108.788604.
R. J. Myerburg and M. J. Junttila, “Sudden Cardiac Death Caused by Coronary Heart Disease,” Circulation 125, no. 8 (2012): 1043–1052, https://doi.org/10.1161/CIRCULATIONAHA.111.023846.
N. Dagres, N. Peek, C. Leclercq, and G. Hindricks, “The PROFID Project,” European Heart Journal 41, no. 39 (2020): 3781–3782, https://doi.org/10.1093/eurheartj/ehaa645.